



27 June 2024

**Our Ref:** RFI 58938

**Freedom of Information Act 2000  
Information in Relation to the Usage of New Biologic and Targeted Medicines  
within Dermatology Medicine**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 4 June 2024.

A response to the question raised has been provided by Surgery & Elective, Maternity & Paediatric Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Manning**  
**Information Governance Officer**

**Q1. How many patients were treated in May 2024 (or latest available month) by the Dermatology department with the following drugs:**

- **Abrocitinib (Cibinqo)**
- **Baricitinib (Olumiant)**
- **Dupilumab (Dupixent)**
- **Lebrikizumab (Ebglyss)**
- **Tralokinumab (Adtralza)**
- **Upadacitinib (Rinvoq)**

A1. Please see Table 1 for the number of patients treated with the listed medication by the Dermatology Department from 01/10/2023 to 31/10/2023.

Please note, the Trust can only provide figures up to 31 October 2023 due to migrating to the new Encompass system.

Table 1

<b>Treatment</b>	<b>No. of Patients Treated</b>
Abrocitinib (Cibinqo)	Nil
Baricitinib (Olumiant)	Nil
Dupilumab (Dupixent)	57
Lebrikizumab (Ebglyss)	Nil
Tralokinumab (Adtralza)	Nil
Upadacitinib (Rinvoq)	4